Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented at the ESMO 2026 Presidential Symposium

Akeso announced the presentation of results from its randomized, controlled, double-blind, multicenter Phase III HARMONi-GI1 trial (AK112-309), which evaluated ivonescimab plus another treatment. The article text is truncated before identifying the combination partner or reporting any efficacy or safety results, so the trial outcome cannot be assessed.